Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005 Oct 01; 104(7):1442-52.
-
Adult
-
Aged
-
Aged, 80 and over
-
Aminoglycosides
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antigens, CD
-
Antigens, Differentiation, Myelomonocytic
-
Clinical Trials, Phase II as Topic
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Evaluation Studies as Topic
-
Female
-
Follow-Up Studies
-
Humans
-
Leukemia, Myeloid, Acute
-
Male
-
Maximum Tolerated Dose
-
Middle Aged
-
Recurrence
-
Risk Assessment
-
Severity of Illness Index
-
Single-Blind Method
-
Survival Rate
-
Treatment Outcome